Early Addition of Selexipag to Double Therapy for Pulmonary Arterial Hypertension.

ABSTRACT:

Importance

A subgroup analysis of a randomized clinical trial established the efficacy of selexipag plus background therapy (monotherapy or double oral therapy [DOT]) vs placebo plus background therapy and found that the addition of selexipag within 6 months had an added benefit. However, the timing of selexipag addition to DOT and the incremental benefit in clinical practice is not well studied.

Objective

To compare triple oral therapy (TOT) consisting of selexipag, endothelin receptor antagonist (ERA), and phosphodiesterase type 5 inhibitor (PDE5i) vs DOT consisting of ERA and PDE5i.

Design, setting, and participants

This comparative effectiveness study was conducted using data from the US Komodo claims database to emulate a randomized trial. Patients aged 18 years

SUBMITTER: Burger CD 

PROVIDER: S-EPMC11420696 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature